{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T11:21:46Z","timestamp":1762168906413,"version":"build-2065373602"},"reference-count":105,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardio-Oncology"],"DOI":"10.1186\/s40959-025-00396-5","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T09:32:10Z","timestamp":1762162330000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mutational analysis of the mitochondrial tRNA genes and flanking regions in lymphocytes from long-term pediatric cancer survivors given doxorubicin chemotherapy for acute lymphoblastic leukemia"],"prefix":"10.1186","volume":"11","author":[{"given":"Vernon E.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neha","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salina M.","family":"Torres","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kristen","family":"Stevenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yael","family":"Flamand","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dale M.","family":"Walker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven E.","family":"Lipshultz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"issue":"12","key":"396_CR1","doi-asserted-by":"publisher","first-page":"808","DOI":"10.1056\/NEJM199103213241205","volume":"324","author":"SE Lipshultz","year":"1991","unstructured":"Lipshultz SE, Colan SD, Gelber RD, Perez-Atayde AR, Sallan SE, Sanders SP. Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med. 1991;324(12):808\u201315.","journal-title":"N Engl J Med"},{"issue":"2","key":"396_CR2","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1200\/JCO.1996.14.2.362","volume":"14","author":"LH Wexler","year":"1996","unstructured":"Wexler LH, Andrich MP, Venzon D, Berg SL, Weaver-McClure L, Chen CC, et al. Randomized trial of the cardioprotective agent ICRF-187 in pediatric sarcoma patients treated with doxorubicin. J Clin Oncol. 1996;14(2):362\u201372.","journal-title":"J Clin Oncol"},{"issue":"6","key":"396_CR3","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1097\/CAD.0b013e32803d36fe","volume":"18","author":"A Longhi","year":"2007","unstructured":"Longhi A, Ferrari S, Bacci G, Specchia S. Long-term follow-up of patients with doxorubicin-induced cardiac toxicity after chemotherapy for osteosarcoma. Anticancer Drugs. 2007;18(6):737\u201344.","journal-title":"Anticancer Drugs"},{"issue":"5","key":"396_CR4","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1309\/AJCPB66LRIIVMQDR","volume":"130","author":"A Dolci","year":"2008","unstructured":"Dolci A, Dominici R, Cardinale D, Sandri MT, Panteghini M. Biochemical markers for prediction of chemotherapy-induced cardiotoxicity: systematic review of the literature and recommendations for use. Am J Clin Pathol. 2008;130(5):688\u201395.","journal-title":"Am J Clin Pathol"},{"issue":"1","key":"396_CR5","first-page":"7","volume":"67","author":"RL Siegel","year":"2017","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer Statistics, 2017. CA Cancer J Clin. 2017;67(1):7\u201330.","journal-title":"CA Cancer J Clin"},{"issue":"11","key":"396_CR6","doi-asserted-by":"publisher","first-page":"678","DOI":"10.1007\/s00431-005-1732-x","volume":"164","author":"L Elbl","year":"2005","unstructured":"Elbl L, Hrstkova H, Tomaskova I, Blazek B, Michalek J. Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by Dexrazoxane in paediatric patients. Eur J Pediatr. 2005;164(11):678\u201384.","journal-title":"Eur J Pediatr"},{"issue":"14","key":"396_CR7","doi-asserted-by":"publisher","first-page":"2328","DOI":"10.1200\/JCO.2008.21.1425","volume":"27","author":"GT Armstrong","year":"2009","unstructured":"Armstrong GT, Liu Q, Yasui Y, Neglia JP, Leisenring W, Robison LL, et al. Late mortality among 5-year survivors of childhood cancer: a summary from the childhood cancer survivor study. J Clin Oncol. 2009;27(14):2328\u201338.","journal-title":"J Clin Oncol"},{"key":"396_CR8","doi-asserted-by":"publisher","first-page":"b4606","DOI":"10.1136\/bmj.b4606","volume":"339","author":"DA Mulrooney","year":"2009","unstructured":"Mulrooney DA, Yeazel MW, Kawashima T, Mertens AC, Mitby P, Stovall M, et al. Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the childhood cancer survivor study cohort. BMJ. 2009;339:b4606.","journal-title":"BMJ"},{"issue":"12","key":"396_CR9","doi-asserted-by":"publisher","first-page":"2629","DOI":"10.1200\/JCO.2005.12.121","volume":"23","author":"SE Lipshultz","year":"2005","unstructured":"Lipshultz SE, Lipsitz SR, Sallan SE, Dalton VM, Mone SM, Gelber RD, et al. Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. J Clin Oncol. 2005;23(12):2629\u201336.","journal-title":"J Clin Oncol"},{"issue":"4","key":"396_CR10","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1093\/annonc\/mdf118","volume":"13","author":"LC Kremer","year":"2002","unstructured":"Kremer LC, van Dalen EC, Offringa M, Vo\u00fbte PA. Frequency and risk factors of anthracycline-induced clinical heart failure in children: a systematic review. Ann Oncol. 2002;13(4):503\u201312.","journal-title":"Ann Oncol"},{"issue":"2","key":"396_CR11","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1016\/j.pcad.2010.06.007","volume":"53","author":"DB Sawyer","year":"2010","unstructured":"Sawyer DB, Peng X, Chen B, Pentassuglia L, Lim CC. Mechanisms of anthracycline cardiac injury: can we identify strategies for cardioprotection? Prog Cardiovasc Dis. 2010;53(2):105\u201313.","journal-title":"Prog Cardiovasc Dis"},{"issue":"6","key":"396_CR12","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s11906-010-0146-y","volume":"12","author":"CA Geisberg","year":"2010","unstructured":"Geisberg CA, Sawyer DB. Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Curr Hypertens Rep. 2010;12(6):404\u201310.","journal-title":"Curr Hypertens Rep"},{"issue":"12","key":"396_CR13","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1056\/NEJMcibr1214975","volume":"368","author":"DB Sawyer","year":"2013","unstructured":"Sawyer DB. Anthracyclines and heart failure. N Engl J Med. 2013;368(12):1154\u20136.","journal-title":"N Engl J Med"},{"issue":"2","key":"396_CR14","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1124\/mol.119.115725","volume":"96","author":"N Wenningmann","year":"2019","unstructured":"Wenningmann N, Knapp M, Ande A, Vaidya TR, Ait-Oudhia S. Insights into Doxorubicin-induced cardiotoxicity: molecular Mechanisms, preventive Strategies, and early monitoring. Mol Pharmacol. 2019;96(2):219\u201332.","journal-title":"Mol Pharmacol"},{"issue":"1","key":"396_CR15","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1038\/s41514-024-00135-7","volume":"10","author":"AN Linders","year":"2024","unstructured":"Linders AN, Dias IB, L\u00f3pez Fern\u00e1ndez T, Tocchetti CG, Bomer N, Van der Meer P. A review of the pathophysiological mechanisms of doxorubicin-induced cardiotoxicity and aging. NPJ Aging. 2024;10(1):9.","journal-title":"NPJ Aging"},{"key":"396_CR16","doi-asserted-by":"publisher","first-page":"13","DOI":"10.3390\/ijms25137477","volume":"25","author":"R Vitale","year":"2024","unstructured":"Vitale R, Marzocco S, Popolo A. Role of oxidative stress and inflammation in Doxorubicin-Induced cardiotoxicity: A brief account. Int J Mol Sci. 2024;25:13.","journal-title":"Int J Mol Sci"},{"issue":"19","key":"396_CR17","doi-asserted-by":"publisher","first-page":"2423","DOI":"10.1161\/01.CIR.0000093196.59829.DF","volume":"108","author":"D Lebrecht","year":"2003","unstructured":"Lebrecht D, Setzer B, Ketelsen UP, Haberstroh J, Walker UA. Time-dependent and tissue-specific accumulation of MtDNA and respiratory chain defects in chronic doxorubicin cardiomyopathy. Circulation. 2003;108(19):2423\u20139.","journal-title":"Circulation"},{"issue":"2","key":"396_CR18","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1124\/pr.56.2.6","volume":"56","author":"G Minotti","year":"2004","unstructured":"Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L. Anthracyclines: molecular advances and Pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev. 2004;56(2):185\u2013229.","journal-title":"Pharmacol Rev"},{"issue":"1\u20132","key":"396_CR19","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1006\/mgme.2000.3043","volume":"71","author":"MS Horenstein","year":"2000","unstructured":"Horenstein MS, Vander Heide RS, L\u2019Ecuyer TJ. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Mol Genet Metab. 2000;71(1\u20132):436\u201344.","journal-title":"Mol Genet Metab"},{"issue":"22","key":"396_CR20","doi-asserted-by":"publisher","first-page":"3777","DOI":"10.1200\/JCO.2007.14.9401","volume":"26","author":"L Gianni","year":"2008","unstructured":"Gianni L, Herman EH, Lipshultz SE, Minotti G, Sarvazyan N, Sawyer DB. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol. 2008;26(22):3777\u201384.","journal-title":"J Clin Oncol"},{"issue":"2","key":"396_CR21","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1007\/s12012-007-0009-1","volume":"7","author":"D Lebrecht","year":"2007","unstructured":"Lebrecht D, Walker UA. Role of MtDNA lesions in anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7(2):108\u201313.","journal-title":"Cardiovasc Toxicol"},{"issue":"17","key":"396_CR22","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1161\/CIR.0b013e3182a88099","volume":"128","author":"SE Lipshultz","year":"2013","unstructured":"Lipshultz SE, Adams MJ, Colan SD, Constine LS, Herman EH, Hsu DT, et al. Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American heart association. Circulation. 2013;128(17):1927\u201395.","journal-title":"Circulation"},{"issue":"2","key":"396_CR23","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1007\/s12012-007-0011-7","volume":"7","author":"P Menna","year":"2007","unstructured":"Menna P, Recalcati S, Cairo G, Minotti G. An introduction to the metabolic determinants of anthracycline cardiotoxicity. Cardiovasc Toxicol. 2007;7(2):80\u20135.","journal-title":"Cardiovasc Toxicol"},{"issue":"12","key":"396_CR24","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1038\/nrclinonc.2013.195","volume":"10","author":"SE Lipshultz","year":"2013","unstructured":"Lipshultz SE, Cochran TR, Franco VI, Miller TL. Treatment-related cardiotoxicity in survivors of childhood cancer. Nat Rev Clin Oncol. 2013;10(12):697\u2013710.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"396_CR25","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/0005-2736(85)90195-6","volume":"819","author":"K Nicolay","year":"1985","unstructured":"Nicolay K, van der Neut R, Fok JJ, de Kruijff B. Effects of adriamycin on lipid polymorphism in cardiolipin-containing model and mitochondrial membranes. Biochim Biophys Acta. 1985;819(1):55\u201365.","journal-title":"Biochim Biophys Acta"},{"issue":"4","key":"396_CR26","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.breast.2009.05.004","volume":"18","author":"RC Leonard","year":"2009","unstructured":"Leonard RC, Williams S, Tulpule A, Levine AM, Oliveros S. Improving the therapeutic index of anthracycline chemotherapy: focus on liposomal doxorubicin (Myocet). Breast. 2009;18(4):218\u201324.","journal-title":"Breast"},{"issue":"6","key":"396_CR27","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/sj.bjp.0707294","volume":"151","author":"D Lebrecht","year":"2007","unstructured":"Lebrecht D, Geist A, Ketelsen UP, Haberstroh J, Setzer B, Walker UA. Dexrazoxane prevents doxorubicin-induced long-term cardiotoxicity and protects myocardial mitochondria from genetic and functional lesions in rats. Br J Pharmacol. 2007;151(6):771\u20138.","journal-title":"Br J Pharmacol"},{"issue":"4","key":"396_CR28","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/path.1863","volume":"207","author":"D Lebrecht","year":"2005","unstructured":"Lebrecht D, Kokkori A, Ketelsen UP, Setzer B, Walker UA. Tissue-specific MtDNA lesions and radical-associated mitochondrial dysfunction in human hearts exposed to doxorubicin. J Pathol. 2005;207(4):436\u201344.","journal-title":"J Pathol"},{"issue":"2","key":"396_CR29","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1006\/bbrc.1993.2135","volume":"195","author":"K Adachi","year":"1993","unstructured":"Adachi K, Fujiura Y, Mayumi F, Nozuhara A, Sugiu Y, Sakanashi T, et al. A deletion of mitochondrial DNA in murine doxorubicin-induced cardiotoxicity. Biochem Biophys Res Commun. 1993;195(2):945\u201351.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"396_CR30","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1006\/bbrc.1998.0124","volume":"254","author":"A Kotsinas","year":"1999","unstructured":"Kotsinas A, Gorgoulis V, Zacharatos P, Zioris H, Triposkiadis F, Donta I, et al. Antioxidant agent nimesulid and beta-blocker Metoprolol do not exert protective effects against rat mitochondrial DNA alterations in adriamycin-induced cardiotoxicity. Biochem Biophys Res Commun. 1999;254(3):651\u20136.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"396_CR31","first-page":"771","volume":"61","author":"S Zhou","year":"2001","unstructured":"Zhou S, Starkov A, Froberg MK, Leino RL, Wallace KB. Cumulative and irreversible cardiac mitochondrial dysfunction induced by doxorubicin. Cancer Res. 2001;61(2):771\u20137.","journal-title":"Cancer Res"},{"issue":"6","key":"396_CR32","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1002\/cncr.29872","volume":"122","author":"SE Lipshultz","year":"2016","unstructured":"Lipshultz SE, Anderson LM, Miller TL, Gerschenson M, Stevenson KE, Neuberg DS, et al. Impaired mitochondrial function is abrogated by Dexrazoxane in doxorubicin-treated childhood acute lymphoblastic leukemia survivors. Cancer. 2016;122(6):946\u201353.","journal-title":"Cancer"},{"key":"396_CR33","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1016\/j.ppedcard.2014.09.007","volume":"36","author":"SE Lipshultz","year":"2014","unstructured":"Lipshultz SE, Franco VI, Sallan SE, Adamson PC, Steiner R, Swain SM, et al. Dexrazoxane for reducing anthracycline-related cardiotoxicity in children with cancer: an update of the evidence. Prog Pediatr Cardiol. 2014;36:39\u201349.","journal-title":"Prog Pediatr Cardiol"},{"issue":"2","key":"396_CR34","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1056\/NEJMoa035153","volume":"351","author":"SE Lipshultz","year":"2004","unstructured":"Lipshultz SE, Rifai N, Dalton VM, Levy DE, Silverman LB, Lipsitz SR, et al. The effect of Dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. N Engl J Med. 2004;351(2):145\u201353.","journal-title":"N Engl J Med"},{"issue":"10","key":"396_CR35","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1016\/S1470-2045(10)70204-7","volume":"11","author":"SE Lipshultz","year":"2010","unstructured":"Lipshultz SE, Scully RE, Lipsitz SR, Sallan SE, Silverman LB, Miller TL, et al. Assessment of Dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial. Lancet Oncol. 2010;11(10):950\u201361.","journal-title":"Lancet Oncol"},{"issue":"18","key":"396_CR36","doi-asserted-by":"publisher","first-page":"5430","DOI":"10.1093\/nar\/gkh884","volume":"32","author":"L Levinger","year":"2004","unstructured":"Levinger L, M\u00f6rl M, Florentz C. Mitochondrial tRNA 3\u2019 end metabolism and human disease. Nucleic Acids Res. 2004;32(18):5430\u201341.","journal-title":"Nucleic Acids Res"},{"issue":"Database issue","key":"396_CR37","doi-asserted-by":"publisher","first-page":"D823","DOI":"10.1093\/nar\/gkl927","volume":"35","author":"E Ruiz-Pesini","year":"2007","unstructured":"Ruiz-Pesini E, Lott MT, Procaccio V, Poole JC, Brandon MC, Mishmar D, et al. An enhanced MITOMAP with a global MtDNA mutational phylogeny. Nucleic Acids Res. 2007;35(Database issue):D823\u20138.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"396_CR38","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/em.20433","volume":"50","author":"SM Torres","year":"2009","unstructured":"Torres SM, Walker DM, McCash CL, Carter MM, Ming J, Cordova EM, et al. Mutational analysis of the mitochondrial tRNA genes and flanking regions in umbilical cord tissue from uninfected infants receiving AZT-based therapies for prophylaxis of HIV-1. Environ Mol Mutagen. 2009;50(1):10\u201326.","journal-title":"Environ Mol Mutagen"},{"key":"396_CR39","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1016\/0076-6879(87)55032-7","volume":"155","author":"LS Lerman","year":"1987","unstructured":"Lerman LS, Silverstein K. Computational simulation of DNA melting and its application to denaturing gradient gel electrophoresis. Methods Enzymol. 1987;155:482\u2013501.","journal-title":"Methods Enzymol"},{"issue":"17","key":"396_CR40","doi-asserted-by":"publisher","first-page":"7866","DOI":"10.1073\/pnas.89.17.7866","volume":"89","author":"TR Skopek","year":"1992","unstructured":"Skopek TR, Walker VE, Cochrane JE, Craft TR, Cariello NF. Mutational spectrum at the Hprt locus in Splenic T cells of B6C3F1 mice exposed to N-ethyl-N-nitrosourea. Proc Natl Acad Sci U S A. 1992;89(17):7866\u201370.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"12","key":"396_CR41","doi-asserted-by":"publisher","first-page":"2455","DOI":"10.1093\/nar\/25.12.2455","volume":"25","author":"Y Michikawa","year":"1997","unstructured":"Michikawa Y, Hofhaus G, Lerman LS, Attardi G. Comprehensive, rapid and sensitive detection of sequence variants of human mitochondrial tRNA genes. Nucleic Acids Res. 1997;25(12):2455\u201363.","journal-title":"Nucleic Acids Res"},{"issue":"5440","key":"396_CR42","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1126\/science.286.5440.774","volume":"286","author":"Y Michikawa","year":"1999","unstructured":"Michikawa Y, Mazzucchelli F, Bresolin N, Scarlato G, Attardi G. Aging-dependent large accumulation of point mutations in the human MtDNA control region for replication. Science. 1999;286(5440):774\u20139.","journal-title":"Science"},{"issue":"1\u20132","key":"396_CR43","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1567-7249(02)00032-6","volume":"2","author":"G Attardi","year":"2002","unstructured":"Attardi G. Role of mitochondrial DNA in human aging. Mitochondrion. 2002;2(1\u20132):27\u201337.","journal-title":"Mitochondrion"},{"issue":"5","key":"396_CR44","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1016\/j.echo.2010.03.019","volume":"23","author":"L Lopez","year":"2010","unstructured":"Lopez L, Colan SD, Frommelt PC, Ensing GJ, Kendall K, Younoszai AK, et al. Recommendations for quantification methods during the performance of a pediatric echocardiogram: a report from the pediatric measurements writing group of the American society of echocardiography pediatric and congenital heart disease Council. J Am Soc Echocardiogr. 2010;23(5):465\u201395. quiz 576-7.","journal-title":"J Am Soc Echocardiogr"},{"issue":"1","key":"396_CR45","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1086\/504926","volume":"79","author":"R Saxena","year":"2006","unstructured":"Saxena R, de Bakker PI, Singer K, Mootha V, Burtt N, Hirschhorn JN, et al. Comprehensive association testing of common mitochondrial DNA variation in metabolic disease. Am J Hum Genet. 2006;79(1):54\u201361.","journal-title":"Am J Hum Genet"},{"issue":"4","key":"396_CR46","first-page":"441","volume":"21","author":"SC Kirchner","year":"2000","unstructured":"Kirchner SC, Hallagan SE, Farin FM, Dilley J, Costa-Mallen P, Smith-Weller T, et al. Mitochondrial ND1 sequence analysis and association of the T4216C mutation with parkinson\u2019s disease. Neurotoxicology. 2000;21(4):441\u20135.","journal-title":"Neurotoxicology"},{"issue":"2","key":"396_CR47","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/S0006-291X(02)00672-1","volume":"295","author":"S Fauser","year":"2002","unstructured":"Fauser S, Luberichs J, Besch D, Leo-Kottler B. Sequence analysis of the complete mitochondrial genome in patients with leber\u2019s hereditary optic neuropathy lacking the three most common pathogenic DNA mutations. Biochem Biophys Res Commun. 2002;295(2):342\u20137.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2\u20133","key":"396_CR48","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.neulet.2004.08.012","volume":"370","author":"D Otaegui","year":"2004","unstructured":"Otaegui D, Pais\u00e1n C, S\u00e1enz A, Mart\u00ed I, Ribate M, Mart\u00ed-Mass\u00f3 JF, et al. Mitochondrial polymporphisms in parkinson\u2019s disease. Neurosci Lett. 2004;370(2\u20133):171\u20134.","journal-title":"Neurosci Lett"},{"issue":"2","key":"396_CR49","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1136\/jmg.2005.032474","volume":"43","author":"AL Mitchell","year":"2006","unstructured":"Mitchell AL, Elson JL, Howell N, Taylor RW, Turnbull DM. Sequence variation in mitochondrial complex I genes: mutation or polymorphism? J Med Genet. 2006;43(2):175\u20139.","journal-title":"J Med Genet"},{"key":"396_CR50","volume-title":"Developing a DNA microarray for human ancestry and migration","author":"JL T","year":"2007","unstructured":"JL T. Developing a DNA microarray for human ancestry and migration. Medord, MA: Tufts University; 2007."},{"issue":"5","key":"396_CR51","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/S0002-9440(10)61132-7","volume":"160","author":"V M\u00e1ximo","year":"2002","unstructured":"M\u00e1ximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Sim\u00f5es M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on H\u00fcrthle cell tumors. Am J Pathol. 2002;160(5):1857\u201365.","journal-title":"Am J Pathol"},{"issue":"12","key":"396_CR52","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1016\/j.tig.2004.09.014","volume":"20","author":"R McFarland","year":"2004","unstructured":"McFarland R, Elson JL, Taylor RW, Howell N, Turnbull DM. Assigning pathogenicity to mitochondrial tRNA mutations: when definitely maybe is not good enough. Trends Genet. 2004;20(12):591\u20136.","journal-title":"Trends Genet"},{"issue":"1","key":"396_CR53","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/0006-291X(91)92014-B","volume":"177","author":"T Ozawa","year":"1991","unstructured":"Ozawa T, Tanaka M, Sugiyama S, Ino H, Ohno K, Hattori K, et al. Patients with idiopathic cardiomyopathy belong to the same mitochondrial DNA gene family of parkinson\u2019s disease and mitochondrial encephalomyopathy. Biochem Biophys Res Commun. 1991;177(1):518\u201325.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"396_CR54","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.1016\/0006-291X(91)90399-R","volume":"176","author":"KL Yoon","year":"1991","unstructured":"Yoon KL, Aprille JR, Ernst SG. Mitochondrial tRNA(thr) mutation in fatal infantile respiratory enzyme deficiency. Biochem Biophys Res Commun. 1991;176(3):1112\u20135.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"396_CR55","first-page":"446","volume":"51","author":"MD Brown","year":"1992","unstructured":"Brown MD, Torroni A, Shoffner JM, Wallace DC. Mitochondrial tRNA(Thr) mutations and lethal infantile mitochondrial myopathy. Am J Hum Genet. 1992;51(2):446\u20137.","journal-title":"Am J Hum Genet"},{"issue":"2","key":"396_CR56","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1016\/j.bbrc.2004.04.061","volume":"318","author":"V Ruppert","year":"2004","unstructured":"Ruppert V, Nolte D, Aschenbrenner T, Pankuweit S, Funck R, Maisch B. Novel point mutations in the mitochondrial DNA detected in patients with dilated cardiomyopathy by screening the whole mitochondrial genome. Biochem Biophys Res Commun. 2004;318(2):535\u201343.","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"396_CR57","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1053\/ajkd.2001.26848","volume":"38","author":"B Watson Jr","year":"2001","unstructured":"Watson B Jr., Khan MA, Desmond RA, Bergman S. Mitochondrial DNA mutations in black Americans with hypertension-associated end-stage renal disease. Am J Kidney Dis. 2001;38(3):529\u201336.","journal-title":"Am J Kidney Dis"},{"issue":"16","key":"396_CR58","doi-asserted-by":"publisher","first-page":"2060","DOI":"10.1038\/sj.onc.1203537","volume":"19","author":"JJ Yeh","year":"2000","unstructured":"Yeh JJ, Lunetta KL, van Orsouw NJ, Moore FD Jr., Mutter GL, Vijg J, et al. Somatic mitochondrial DNA (mtDNA) mutations in papillary thyroid carcinomas and differential MtDNA sequence variants in cases with thyroid tumours. Oncogene. 2000;19(16):2060\u20136.","journal-title":"Oncogene"},{"issue":"16","key":"396_CR59","doi-asserted-by":"publisher","first-page":"2415","DOI":"10.1093\/hmg\/ddi243","volume":"14","author":"FA Kondrashov","year":"2005","unstructured":"Kondrashov FA. Prediction of pathogenic mutations in mitochondrially encoded human tRNAs. Hum Mol Genet. 2005;14(16):2415\u20139.","journal-title":"Hum Mol Genet"},{"issue":"10","key":"396_CR60","doi-asserted-by":"publisher","first-page":"1356","DOI":"10.1017\/S1355838200001047","volume":"6","author":"M Helm","year":"2000","unstructured":"Helm M, Brul\u00e9 H, Friede D, Gieg\u00e9 R, P\u00fctz D, Florentz C. Search for characteristic structural features of mammalian mitochondrial tRNAs. RNA. 2000;6(10):1356\u201379.","journal-title":"RNA"},{"issue":"3","key":"396_CR61","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.yjmcc.2006.06.009","volume":"41","author":"M Tokarska-Schlattner","year":"2006","unstructured":"Tokarska-Schlattner M, Zaugg M, Zuppinger C, Wallimann T, Schlattner U. New insights into doxorubicin-induced cardiotoxicity: the critical role of cellular energetics. J Mol Cell Cardiol. 2006;41(3):389\u2013405.","journal-title":"J Mol Cell Cardiol"},{"issue":"11","key":"396_CR62","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1182\/blood.V110.11.2800.2800","volume":"110","author":"SE Lipshultz","year":"2007","unstructured":"Lipshultz SE, Walker VE, Torres SM, Walker DM, Barry E, Miller TL, et al. Frequent mitochondrial DNA mutations and polymorphisms in Long-Term survivors of childhood acute lymphoblastic leukemia. Blood. 2007;110(11):2800.","journal-title":"Blood"},{"issue":"6","key":"396_CR63","doi-asserted-by":"publisher","first-page":"e239","DOI":"10.1097\/MPH.0b013e31820a5ece","volume":"33","author":"CS Kwok","year":"2011","unstructured":"Kwok CS, Quah TC, Ariffin H, Tay SK, Yeoh AE. Mitochondrial D-loop polymorphisms and mitochondrial DNA content in childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2011;33(6):e239\u201344.","journal-title":"J Pediatr Hematol Oncol"},{"issue":"1","key":"396_CR64","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/S0008-6363(00)00241-8","volume":"49","author":"J Marin-Garcia","year":"2001","unstructured":"Marin-Garcia J, Goldenthal MJ, Moe GW. Mitochondrial pathology in cardiac failure. Cardiovasc Res. 2001;49(1):17\u201326.","journal-title":"Cardiovasc Res"},{"issue":"7","key":"396_CR65","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1016\/j.bbamcr.2010.11.017","volume":"1813","author":"RA Gottlieb","year":"2011","unstructured":"Gottlieb RA, Gustafsson AB. Mitochondrial turnover in the heart. Biochim Biophys Acta. 2011;1813(7):1295\u2013301.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"396_CR66","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1080\/17425255.2017.1351547","volume":"13","author":"N Bansal","year":"2017","unstructured":"Bansal N, Amdani S, Lipshultz ER, Lipshultz SE. Chemotherapy-induced cardiotoxicity in children. Expert Opin Drug Metab Toxicol. 2017;13(8):817\u201332.","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"10","key":"396_CR67","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1016\/j.hlc.2019.08.002","volume":"28","author":"AJ Croft","year":"2019","unstructured":"Croft AJ, Ngo DTM, Sverdlov AL. Anthracycline-Induced cardiotoxicity: time to focus on cardioprotection again. Heart Lung Circ. 2019;28(10):1454\u20136.","journal-title":"Heart Lung Circ"},{"issue":"2","key":"396_CR68","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1172\/JCI72931","volume":"124","author":"Y Ichikawa","year":"2014","unstructured":"Ichikawa Y, Ghanefar M, Bayeva M, Wu R, Khechaduri A, Naga Prasad SV, et al. Cardiotoxicity of doxorubicin is mediated through mitochondrial iron accumulation. J Clin Invest. 2014;124(2):617\u201330.","journal-title":"J Clin Invest"},{"issue":"3","key":"396_CR69","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1034\/j.1600-0773.2003.930301.x","volume":"93","author":"KB Wallace","year":"2003","unstructured":"Wallace KB. Doxorubicin-induced cardiac mitochondrionopathy. Pharmacol Toxicol. 2003;93(3):105\u201315.","journal-title":"Pharmacol Toxicol"},{"issue":"1","key":"396_CR70","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ccell.2016.11.011","volume":"31","author":"KA Sarosiek","year":"2017","unstructured":"Sarosiek KA, Fraser C, Muthalagu N, Bhola PD, Chang W, McBrayer SK, et al. Developmental regulation of mitochondrial apoptosis by c-Myc governs Age- and Tissue-Specific sensitivity to cancer therapeutics. Cancer Cell. 2017;31(1):142\u201356.","journal-title":"Cancer Cell"},{"issue":"19","key":"396_CR71","doi-asserted-by":"publisher","first-page":"e029954","DOI":"10.1161\/JAHA.123.029954","volume":"12","author":"P Singh","year":"2023","unstructured":"Singh P, Shah DA, Jouni M, Cejas RB, Crossman DK, Magdy T, et al. Altered peripheral blood gene expression in childhood cancer survivors with Anthracycline-Induced Cardiomyopathy - A COG-ALTE03N1 report. J Am Heart Assoc. 2023;12(19):e029954.","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"396_CR72","doi-asserted-by":"publisher","first-page":"1758","DOI":"10.1200\/JCO.22.01527","volume":"41","author":"X Wang","year":"2023","unstructured":"Wang X, Singh P, Zhou L, Sharafeldin N, Landier W, Hageman L, et al. Genome-Wide association study identifies ROBO2 as a novel susceptibility gene for Anthracycline-Related cardiomyopathy in childhood cancer survivors. J Clin Oncol. 2023;41(9):1758\u201369.","journal-title":"J Clin Oncol"},{"issue":"6","key":"396_CR73","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1016\/j.leukres.2012.02.017","volume":"36","author":"J Savatier","year":"2012","unstructured":"Savatier J, Rharass T, Canal C, Gbankoto A, Vigo J, Salmon JM, et al. Adriamycin dose and time effects on cell cycle, cell death, and reactive oxygen species generation in leukaemia cells. Leuk Res. 2012;36(6):791\u20138.","journal-title":"Leuk Res"},{"issue":"5","key":"396_CR74","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1159\/000245937","volume":"84","author":"HS Kim","year":"2009","unstructured":"Kim HS, Lee YS, Kim DK. Doxorubicin exerts cytotoxic effects through cell cycle arrest and Fas-mediated cell death. Pharmacology. 2009;84(5):300\u20139.","journal-title":"Pharmacology"},{"issue":"6","key":"396_CR75","doi-asserted-by":"publisher","first-page":"1144","DOI":"10.1016\/j.bbamcr.2011.03.002","volume":"1813","author":"AV Kuznetsov","year":"2011","unstructured":"Kuznetsov AV, Margreiter R, Amberger A, Saks V, Grimm M. Changes in mitochondrial redox state, membrane potential and calcium precede mitochondrial dysfunction in doxorubicin-induced cell death. Biochim Biophys Acta. 2011;1813(6):1144\u201352.","journal-title":"Biochim Biophys Acta"},{"issue":"8","key":"396_CR76","first-page":"Xc01","volume":"10","author":"R Mishra","year":"2016","unstructured":"Mishra R, Khurana R, Mishra H, Rastogi M, Hadi R. Retrospective analysis of efficacy and toxicity of Hypo-fractionated radiotherapy in breast carcinoma. J Clin Diagn Res. 2016;10(8):Xc01\u20133.","journal-title":"J Clin Diagn Res"},{"issue":"18","key":"396_CR77","doi-asserted-by":"publisher","first-page":"4737","DOI":"10.1158\/1078-0432.CCR-14-0821","volume":"20","author":"KC Nitiss","year":"2014","unstructured":"Nitiss KC, Nitiss JL. Twisting and ironing: doxorubicin cardiotoxicity by mitochondrial DNA damage. Clin Cancer Res. 2014;20(18):4737\u20139.","journal-title":"Clin Cancer Res"},{"issue":"2\u20133","key":"396_CR78","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1002\/(SICI)1098-2280(1999)34:2\/3<154::AID-EM15>3.0.CO;2-0","volume":"34","author":"NJ Gorelick","year":"1999","unstructured":"Gorelick NJ, Andrews JL, deBoer JG, Young R, Gibson DP, Walker VE. Tissue-specific mutant frequencies and mutational spectra in cyclophosphamide-treated LacI Transgenic mice. Environ Mol Mutagen. 1999;34(2\u20133):154\u201366.","journal-title":"Environ Mol Mutagen"},{"issue":"2\u20133","key":"396_CR79","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/(SICI)1098-2280(1999)34:2\/3<167::AID-EM16>3.0.CO;2-O","volume":"34","author":"VE Walker","year":"1999","unstructured":"Walker VE, Andrews JL, Upton PB, Skopek TR, deBoer JG, Walker DM, et al. Detection of cyclophosphamide-induced mutations at the Hprt but not the LacI locus in Splenic lymphocytes of exposed mice. Environ Mol Mutagen. 1999;34(2\u20133):167\u201381.","journal-title":"Environ Mol Mutagen"},{"issue":"1\u20132","key":"396_CR80","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/S0027-5107(03)00072-1","volume":"527","author":"A Aidoo","year":"2003","unstructured":"Aidoo A, Mittelstaedt RA, Bishop ME, Lyn-Cook LE, Chen YJ, Duffy P, et al. Effect of caloric restriction on Hprt lymphocyte mutation in aging rats. Mutat Res. 2003;527(1\u20132):57\u201366.","journal-title":"Mutat Res"},{"issue":"3","key":"396_CR81","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S0006-291X(03)00625-9","volume":"304","author":"A Chomyn","year":"2003","unstructured":"Chomyn A, Attardi G. MtDNA mutations in aging and apoptosis. Biochem Biophys Res Commun. 2003;304(3):519\u201329.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"396_CR82","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.1371\/journal.pgen.0030024","volume":"3","author":"GC Kujoth","year":"2007","unstructured":"Kujoth GC, Bradshaw PC, Haroon S, Prolla TA. The role of mitochondrial DNA mutations in mammalian aging. PLoS Genet. 2007;3(2):e24.","journal-title":"PLoS Genet"},{"issue":"10","key":"396_CR83","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1016\/j.bbagen.2009.04.012","volume":"1790","author":"YS Ma","year":"2009","unstructured":"Ma YS, Wu SB, Lee WY, Cheng JS, Wei YH. Response to the increase of oxidative stress and mutation of mitochondrial DNA in aging. Biochim Biophys Acta. 2009;1790(10):1021\u20139.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"396_CR84","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0921-8777(94)90010-8","volume":"315","author":"H Hirota","year":"1994","unstructured":"Hirota H, Kubota M, Adachi S, Okuda A, Lin YW, Bessho R, et al. Somatic mutations at T-cell antigen receptor and Glycophorin A loci in pediatric leukemia patients following chemotherapy: comparison with HPRT locus mutation. Mutat Res. 1994;315(2):95\u2013103.","journal-title":"Mutat Res"},{"issue":"2","key":"396_CR85","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0027-5107(98)00199-7","volume":"422","author":"S Koishi","year":"1998","unstructured":"Koishi S, Kubota M, Sawada M, Hirota H, Hashimoto H, Lin YW, et al. Biomarkers in long survivors of pediatric acute lymphoblastic leukemia patients: late effects of cancer chemotherapy. Mutat Res. 1998;422(2):213\u201322.","journal-title":"Mutat Res"},{"issue":"13","key":"396_CR86","doi-asserted-by":"publisher","first-page":"4464","DOI":"10.1158\/0008-5472.CAN-03-3940","volume":"64","author":"SC Rice","year":"2004","unstructured":"Rice SC, Vacek P, Homans AH, Messier T, Rivers J, Kendall H, et al. Genotoxicity of therapeutic intervention in children with acute lymphocytic leukemia. Cancer Res. 2004;64(13):4464\u201371.","journal-title":"Cancer Res"},{"issue":"2","key":"396_CR87","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/0165-1218(93)90069-P","volume":"319","author":"H Hirota","year":"1993","unstructured":"Hirota H, Kubota M, Hashimoto H, Adachi S, Matsubara K, Kuwakado K, et al. Analysis of Hprt gene mutation following anti-cancer treatment in pediatric patients with acute leukemia. Mutat Res. 1993;319(2):113\u201320.","journal-title":"Mutat Res"},{"issue":"2","key":"396_CR88","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1200\/JCO.1996.14.2.328","volume":"14","author":"SE Lipshultz","year":"1996","unstructured":"Lipshultz SE. Dexrazoxane for protection against cardiotoxic effects of anthracyclines in children. J Clin Oncol. 1996;14(2):328\u201331.","journal-title":"J Clin Oncol"},{"issue":"12","key":"396_CR89","doi-asserted-by":"publisher","first-page":"2248","DOI":"10.1200\/JCO.22.02423","volume":"41","author":"EJ Chow","year":"2023","unstructured":"Chow EJ, Aggarwal S, Doody DR, Aplenc R, Armenian SH, Baker KS, et al. Dexrazoxane and Long-Term heart function in survivors of childhood cancer. J Clin Oncol. 2023;41(12):2248\u201357.","journal-title":"J Clin Oncol"},{"key":"396_CR90","first-page":"15","volume":"5","author":"LM Kopp","year":"2019","unstructured":"Kopp LM, Womer RB, Schwartz CL, Ebb DH, Franco VI, Hall D, et al. Effects of Dexrazoxane on doxorubicin-related cardiotoxicity and second malignant neoplasms in children with osteosarcoma: a report from the children\u2019s oncology group. Cardiooncology. 2019;5:15.","journal-title":"Cardiooncology"},{"issue":"3","key":"396_CR91","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1042\/BJ20082427","volume":"422","author":"GW Morris","year":"2009","unstructured":"Morris GW, Iams TA, Slepchenko KG, McKee EE. Origin of pyrimidine deoxyribonucleotide pools in perfused rat heart: implications for 3\u2019-azido-3\u2019-deoxythymidine-dependent cardiotoxicity. Biochem J. 2009;422(3):513\u201320.","journal-title":"Biochem J"},{"issue":"3","key":"396_CR92","doi-asserted-by":"publisher","first-page":"H1273","DOI":"10.1152\/ajpheart.00738.2005","volume":"291","author":"T L\u2019Ecuyer","year":"2006","unstructured":"L\u2019Ecuyer T, Sanjeev S, Thomas R, Novak R, Das L, Campbell W, et al. DNA damage is an early event in doxorubicin-induced cardiac myocyte death. Am J Physiol Heart Circ Physiol. 2006;291(3):H1273\u201380.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"18","key":"396_CR93","doi-asserted-by":"publisher","first-page":"8839","DOI":"10.1158\/0008-5472.CAN-07-1649","volume":"67","author":"YL Lyu","year":"2007","unstructured":"Lyu YL, Kerrigan JE, Lin CP, Azarova AM, Tsai YC, Ban Y, et al. Topoisomerase IIbeta mediated DNA double-strand breaks: implications in doxorubicin cardiotoxicity and prevention by Dexrazoxane. Cancer Res. 2007;67(18):8839\u201346.","journal-title":"Cancer Res"},{"issue":"10","key":"396_CR94","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1086\/429697","volume":"191","author":"PW Mallon","year":"2005","unstructured":"Mallon PW, Unemori P, Sedwell R, Morey A, Rafferty M, Williams K, et al. In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA. J Infect Dis. 2005;191(10):1686\u201396.","journal-title":"J Infect Dis"},{"issue":"4","key":"396_CR95","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s00592-004-0163-x","volume":"41","author":"I Martin-Kleiner","year":"2004","unstructured":"Martin-Kleiner I, Pape-Medvidovi\u0107 E, Pavli\u0107-Renar I, Metelko Z, Kusec R, Gabrilovac J, et al. A pilot study of mitochondrial DNA point mutation A3243G in a sample of Croatian patients having type 2 diabetes mellitus associated with maternal inheritance. Acta Diabetol. 2004;41(4):179\u201384.","journal-title":"Acta Diabetol"},{"issue":"2","key":"396_CR96","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/sj.bjc.6602686","volume":"93","author":"DR Camidge","year":"2005","unstructured":"Camidge DR, Pemberton MN, Growcott JW, Johnstone D, Laud PJ, Foster JR, et al. Assessing proliferation, cell-cycle arrest and apoptotic end points in human buccal punch biopsies for use as pharmacodynamic biomarkers in drug development. Br J Cancer. 2005;93(2):208\u201315.","journal-title":"Br J Cancer"},{"issue":"1","key":"396_CR97","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1158\/1055-9965.EPI-07-0706","volume":"17","author":"G Borthakur","year":"2008","unstructured":"Borthakur G, Butryee C, Stacewicz-Sapuntzakis M, Bowen PE. Exfoliated buccal mucosa cells as a source of DNA to study oxidative stress. Cancer Epidemiol Biomarkers Prev. 2008;17(1):212\u20139.","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"2","key":"396_CR98","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/S0008-6363(95)00209-X","volume":"31","author":"J Marin-Garcia","year":"1996","unstructured":"Marin-Garcia J, Goldenthal MJ, Ananthakrishnan R, Pierpont ME, Fricker FJ, Lipshultz SE, et al. Specific mitochondrial DNA deletions in idiopathic dilated cardiomyopathy. Cardiovasc Res. 1996;31(2):306\u201313.","journal-title":"Cardiovasc Res"},{"issue":"3","key":"396_CR99","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1007\/BF01799259","volume":"19","author":"J Marin-Garcia","year":"1996","unstructured":"Marin-Garcia J, Goldenthal MJ, Ananthakrishnan R, Pierpont ME, Fricker FJ, Lipshultz SE, et al. Mitochondrial function in children with idiopathic dilated cardiomyopathy. J Inherit Metab Dis. 1996;19(3):309\u201312.","journal-title":"J Inherit Metab Dis"},{"key":"396_CR100","doi-asserted-by":"publisher","first-page":"111708","DOI":"10.1016\/j.biopha.2021.111708","volume":"139","author":"PS Rawat","year":"2021","unstructured":"Rawat PS, Jaiswal A, Khurana A, Bhatti JS, Navik U. Doxorubicin-induced cardiotoxicity: an update on the molecular mechanism and novel therapeutic strategies for effective management. Biomed Pharmacother. 2021;139:111708.","journal-title":"Biomed Pharmacother"},{"key":"396_CR101","first-page":"13","volume-title":"McQueen\u2019s comprehensive toxicology","author":"SE Lipshultz","year":"2025","unstructured":"Lipshultz SE, Maywalt D. Anthracycline, trastuzumab, and cardiovascular toxicity. In: Campen M, Farraj A, editors. McQueen\u2019s comprehensive toxicology. 4th ed. Amsterdam: Elsevier Science; 2025. pp. 13\u20135.","edition":"4"},{"key":"396_CR102","doi-asserted-by":"crossref","unstructured":"Bansal N, Amdani S, Akam-Venkata J, Lipshultz ER, Maywalt D, Lipshultz SE. Heart failure in pediatric oncologic disease. In: Rossano J, Jefferies JL, Chang AC, Towbin JA, Shaddy RE, Miyamoto S, editors. Heart failure in the child and young adult: from bench to bedside. Academic; 2025. p. 425\u201343.","DOI":"10.1016\/B978-0-12-802393-8.00032-6"},{"issue":"4","key":"396_CR103","doi-asserted-by":"publisher","first-page":"H702","DOI":"10.1152\/ajpheart.00231.2022","volume":"323","author":"JC Bikomeye","year":"2022","unstructured":"Bikomeye JC, Terwoord JD, Santos JH, Beyer AM. Emerging mitochondrial signaling mechanisms in cardio-oncology: beyond oxidative stress. Am J Physiol Heart Circ Physiol. 2022;323(4):H702\u201320.","journal-title":"Am J Physiol Heart Circ Physiol"},{"issue":"4","key":"396_CR104","doi-asserted-by":"publisher","first-page":"935","DOI":"10.1016\/0735-1097(94)90640-8","volume":"23","author":"AM Remes","year":"1994","unstructured":"Remes AM, Hassinen IE, Ik\u00e4heimo MJ, Herva R, Hirvonen J, Peuhkurinen KJ. Mitochondrial DNA deletions in dilated cardiomyopathy: a clinical study employing endomyocardial sampling. J Am Coll Cardiol. 1994;23(4):935\u201342.","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"396_CR105","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1161\/CIRCRESAHA.109.211276","volume":"106","author":"X Peng","year":"2010","unstructured":"Peng X, Pentassuglia L, Sawyer DB. Emerging anticancer therapeutic targets and the cardiovascular system: is there cause for concern? Circ Res. 2010;106(6):1022\u201334.","journal-title":"Circ Res"}],"container-title":["Cardio-Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00396-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40959-025-00396-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40959-025-00396-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T11:06:22Z","timestamp":1762167982000},"score":1,"resource":{"primary":{"URL":"https:\/\/cardiooncologyjournal.biomedcentral.com\/articles\/10.1186\/s40959-025-00396-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":105,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["396"],"URL":"https:\/\/doi.org\/10.1186\/s40959-025-00396-5","relation":{},"ISSN":["2057-3804"],"issn-type":[{"type":"electronic","value":"2057-3804"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"assertion":[{"value":"5 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the institutional review board of the Dana-Farber Cancer Institute and all subjects provided written informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"99"}}